证券代码：300357 证券简称：我武生物 公告编号：2025-046 浙江我武生物科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 根据浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十五 次会议决议，公司定于 2025 年 12 月 24 日（星期三）下午 14:00 召开公司 2025 年第二 次临时股东会。本次股东会将采取现场投票和网络投票相结合的方式，现将股东会的 有关事项通知如下： 3、会议召开的合法、合规性 公司第五届董事会第十五次会议审议通过《关于召开公司 2025 年第二次临时股东 会的议案》。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件、深圳 证券交易所业务规则和《公司章程》的相关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 24 日 14:00:00 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-043 号 浙江我武生物科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十五次会议 通知于 2025 年 12 月 2 日以邮件方式发出。会议于 2025 年 12 月 8 日在公司上海分公司 会议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席董事 6 人， 实际出席董事 6 人。会议由董事长胡赓熙先生召集并主持，公司部分高级管理人员列席 了会议。本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 本议案已经提名委员会审议通过。 二、董事会会议审议情况 经与会董事认真审议，通过如下议案： 1. 审议通过《关于公司董事会换届选举暨提名第六届董事会非独立董事候选人的 议案》 鉴于公司第五届董事会任期即将届满，公司拟对董事会进行换届选举。经提名委员 会资格审核，董事会同意提名 ...

Core Viewpoint - Iwu Biologics is positioned as a leading enterprise in desensitization therapy in China, with significant advantages in core products and a diversified layout [1] Product Advantages - The dust mite drop solution maintains the highest market share, demonstrating steady growth due to its safety, convenience, and price advantages [1] - The mugwort pollen allergen sublingual drop solution fills a gap in the treatment of pollen allergies in northern regions, showing rapid volume growth and potential as a new growth point for the company [1] Product Strategy - The company has developed a "south mite, north mugwort" product combination and is also expanding into a series of skin prick liquid products [1] - Additionally, the company is proactively exploring cutting-edge fields such as stem cells and natural medicines, creating multidimensional growth support [1] Financial Projections - The company is projected to achieve net profits attributable to the parent company of 399 million, 493 million, and 600 million yuan for the years 2025, 2026, and 2027 respectively [1] - The current stock price corresponds to price-to-earnings ratios of 41.0, 33.3, and 27.3 times for the years 2025, 2026, and 2027 respectively [1] Investment Rating - The report initiates coverage with a "buy" rating for the company [1]

Group 1: Power Industry Insights - The power industry is expected to stabilize as electricity reform accelerates, with a focus on the profitability of thermal power, quality wind power, and opportunities for power equipment exports [6][12] - From January to November 2025, electricity demand in China maintained steady growth, with total electricity consumption reaching 8.62 trillion kWh, a year-on-year increase of 4.8% [6] - The price of thermal coal has rebounded since July 2025, which is anticipated to stabilize electricity prices, with the average monthly trading price in Jiangsu reaching 395.60 RMB/MWh, an increase of 82.80 RMB/MWh [7] Group 2: Hydropower and Nuclear Power - Hydropower companies have shown stable operations, with net interest margins widening in a low-interest-rate environment, making them attractive for long-term investment [8] - The marketization ratio of nuclear power is gradually increasing, with the marketable electricity volume for Lingao and Yangjiang nuclear power plants expected to rise by 14.3% in 2026 [9] Group 3: Green Energy and Equipment - The income policies for green energy have become clearer, with market reforms entering a deeper phase, and the wind power tax subsidy is expected to decline [10] - Investment in domestic power equipment has shown significant growth, with cumulative procurement for the State Grid's transmission and transformation equipment reaching 787.47 billion RMB, a year-on-year increase of 19.6% [11] Group 4: Pharmaceutical Sector - Iwubio - Iwubio is a leading company in the desensitization treatment field, with a strong market position in dust mite drops and a new growth point in the yellow flower pollen sublingual drops [14][15] - The company is expected to achieve net profits of 399 million RMB, 493 million RMB, and 600 million RMB for 2025-2027, with corresponding P/E ratios of 41.0, 33.3, and 27.3 times [14] Group 5: Pharmaceutical Sector - Aladdin - Aladdin has demonstrated significant synergy from external mergers and acquisitions, with revenue for the first three quarters of 2025 reaching 440 million RMB, a year-on-year increase of 17.59% [18] - The company has revised its profit forecasts upward for 2025-2027, expecting net profits of 110 million RMB, 160 million RMB, and 200 million RMB, with corresponding EPS of 0.33, 0.48, and 0.60 RMB [18]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is a leader in the desensitization treatment field, with significant advantages in core products and a diversified layout. Its dust mite drops maintain the highest market share, while the mugwort pollen sublingual drops fill a gap in northern pollen allergy treatment, expected to become a new growth point [5][6]. - The allergic market is expanding, with desensitization therapy showing significant advantages over symptomatic treatments. The domestic anti-allergy drug market is projected to reach 43.67 billion yuan by 2029, driven by rising allergy disease incidence [6][47]. - The company's core products are performing strongly, with the dust mite drops showing a five-year CAGR of 8.86% and revenue of 794 million yuan in the first three quarters of 2025, a 13.38% increase year-on-year. The mugwort pollen drops have a CAGR of 64.71% since their launch in 2021, with a 117.58% increase in revenue in the first three quarters of 2025 [7][8]. Summary by Sections Company Overview - The company, established in 2002, focuses on the research, production, and sales of allergen products, specializing in desensitization drugs and diagnostic reagents [18]. Market Potential - The incidence of allergic diseases is rising, with the anti-allergy drug market in China expected to grow significantly. The desensitization treatment is recognized as the only method that can influence the disease process, unlike symptomatic treatments [6][48]. Product Performance - The dust mite drops have shown strong sales performance, with a revenue CAGR of 8.86% and a gross margin consistently above 95%. The mugwort pollen drops have rapidly gained market share since their launch, with a revenue increase of 117.58% in the first three quarters of 2025 [7][8]. Financial Projections - The company is expected to achieve net profits of 399 million yuan, 493 million yuan, and 600 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 41.0, 33.3, and 27.3 [5][9].

Core Insights - Zhejiang Iwu Biological Technology Co., Ltd. has received approval from the National Medical Products Administration for its "Artemisia pollen prick solution," enhancing its product pipeline in the field of allergic disease diagnosis [1][2] - The approval of the new formulation signifies the company's commitment to innovation and its ability to navigate regulatory processes effectively [1][3] Company Developments - The newly approved product has a total allergen activity of 3500 DU/ml and a packaging volume of 2 ml, complementing the company's existing skin prick diagnostic products [1] - The company has achieved significant financial growth, reporting a revenue of 853 million yuan for the first three quarters of 2025, a year-on-year increase of 16.86%, and a net profit of 345 million yuan, up 26.67% [4] - The core product, dust mite drops, generated approximately 340 million yuan in revenue in Q3 2025, reflecting a year-on-year growth of 17.5% [4] Market Position - Iwu Biological holds over 80% market share in the domestic allergy treatment sector, positioning itself as a leading player in a market with substantial growth potential [5] - The company benefits from a favorable regulatory environment in Zhejiang Province, which supports the development of innovative drugs and medical devices through financial incentives and streamlined approval processes [2][3] R&D and Product Pipeline - The company is transitioning from a product-driven model to a platform-based approach, with a diverse R&D pipeline that includes new products like the Artemisia pollen sublingual drops, which have shown efficacy in clinical trials [4][5] - Recent innovations, such as the dermatitis diagnostic patch, indicate a robust clinical advancement strategy that supports long-term growth [4]

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

Core Viewpoint - The company has received approval for a clinical trial supplement application for its drug "Artemisia pollen puncture solution" from the National Medical Products Administration [2] Group 1 - The company announced on November 21 that it obtained the approval notification for the clinical trial supplement application [2] - The approval was downloaded from the official website of the National Medical Products Administration [2] - The drug in question is referred to as "Artemisia pollen puncture solution" [2]

Core Viewpoint - The Biotech Index (970038) experienced a decline of 2.26% on November 21, closing at 2111.48 points, with a total trading volume of 19.114 billion yuan and a turnover rate of 1.64% [1] Group 1: Index Performance - On the day, only one constituent stock, Prolo Pharmaceutical, saw an increase of 1.41%, while 49 stocks declined, with Iwu Biological leading the drop at 5.0% [1] - The top ten constituent stocks of the Biotech Index are primarily in the biopharmaceutical sector, with significant weightings for companies like Mindray Medical (12.58%) and Changchun High-tech (4.87%) [1] Group 2: Market Capitalization and Price Movements - The total market capitalization of the top ten stocks ranges from 2365.59 billion yuan for Mindray Medical to 285.91 billion yuan for Lepu Medical, indicating a diverse range of company sizes within the index [1] - Price movements for the top stocks include declines for major players such as Mindray Medical (-1.88%) and Changchun High-tech (-2.73%) [1] Group 3: Capital Flow - The Biotech Index constituents saw a net outflow of 1.929 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.724 billion yuan [3] - Notable capital flows include Peak High-Tech with a net inflow of 22.415 million yuan from institutional investors, while other stocks like Jiayuan Pharmaceutical experienced significant outflows [3]

Core Viewpoint - The company, Iwu Biologics (300357.SZ), has received approval for a supplementary application for clinical trials of its drug "Artemisia Pollen Puncture Solution" from the National Medical Products Administration, indicating progress in its product development pipeline [1] Group 1 - The approved clinical trial is aimed at diagnosing Type I hypersensitivity diseases related to ragweed pollen allergy through skin prick tests [1]